Nomination Committee's proposal for election of Board members

Report this content

The Nomination Committee of Bioservo Technologies AB (publ) has decided to propose to the Annual General Meeting the following proposals for the number of Board members and the election of Board members. The Nomination Committee proposes that the number of Board members on the Board should be six (6). The Nomination Committee proposes, for the period until the end of the next Annual General Meeting, re-election of the Board members Anders Lundmark, Runar Bjørklund, Kunal Pandit and Nikolaj Sørensen, as well as new election of Kerstin Valinder Strinnholm and Margit Alt Murphy PhD. As the Chairman of the Board, it is proposed that Anders Lundmark is re-elected. Claes Mellgren has declined re-election.


Kerstin Valinder Strinnholm has many years of experience in sales, marketing and business development from senior positions at Astra/AstraZeneca and Nycomed/Takeda including Executive Vice President Business Development for the Nycomed Group. Currently Kerstin is a board member of Camurus AB, Klifo A/S, KVS Invest AB, Immedica AB, Gedea Biotech AB, Promore Pharma AB and Cavastor AB. She holds a degree from the School of Journalism at the University of Gothenburg.


Margit Alt Murphy PhD is an Associate Professor in Experimental Rehabilitation Medicine at University of Gothenburg and Senior University Hospital Specialist Physiotherapist at Sahlgrenska University Hospital.  Margit is a leading researcher in the field of stroke rehabilitation of upper extremities and has over 40 peer reviewed publications and has received multiple awards for her research. She holds a PhD in Medical Science from the Institute for Neuroscience and Physiology at University of Gothenburg.  


Questions are referred to:

Runar Björklund, Chairman of the Nomination Committee


About Bioservo Technologies

Bioservo Technologies AB (publ) is a world leading company in wearable muscle strengthening systems for people in need of extra strength and endurance. All our innovative products and systems are designed to keep people strong, healthy and efficient.

The company has a unique global position within soft exoskeleton technology for the hand, both for industrial applications to improve the health for workers and to improve quality of life for people with reduced muscle strength.

Bioservo Technologies was founded in 2006 in collaboration between researchers at the Royal Institute of Technology and a doctor at Karolinska University Hospital. Bioservo Technologies is a Swedish public limited company with headquarters in Stockholm.

FNCA Sweden AB, +46(0)8-52800399, is the company’s Certified Adviser on Nasdaq First North Growth Market.

For more information, please visit